0.2 C
New York
Friday, December 2, 2022

Takeda Pharmaceutical Company Limited (NYSE: TAK) Could Achieve Gains In The Near Future

After Hours

It may be riskier to trade before market opening and after market closing than during regular market hours. Since issuers often announce critical financial information outside regular trading hours. Extended-hours trading may result in wider spreads for particular securities due to lower liquidity and higher volatility. After-hours trades for Takeda Pharmaceutical Company Limited (TAK) shows that investor sentiment remained intact, with the stock’s consolidated last price rising by +$0.35, or +2.68%, to $13.4. Volume reached 277 shares, with price reaching a high of $13.6 and a low of $13.6. Yahoo Finance discussed the stock recently as it posted Strengthening Healthcare Systems to Meet Patients’ Need for Plasma-Derived Therapies.

Do You Own These 7 Inflation-Survival Stocks?

Inflation is still near 40-year highs and rising prices are putting a big dent in our wallets. Unless you find out how to protect your portfolio and outpace inflation, you'll keep being at the mercy of economic factors out of your control. Especially since the price of electricity, food, and shelter are creeping up higher than ever. In this special report, I detail 7 stocks to help you survive and thrive in today's market. They're backed by solid companies, positioned to profit during tough economic times, and offer out-sized dividends to help you outpace inflation.

Click here to get your free copy of the report


Stocks Info

Takeda Pharmaceutical Company Limited is listed on the NYSE in the Healthcare sector while operating in the Drug Manufacturers – Specialty & Generic industry. At the end of the last regular session, the stock closed at $13.60 and fluctuated between $13.61 as its day high and $13.34 as its day low. The current market capitalization of Takeda Pharmaceutical Company Limited is $43.46B. A total of 4.8 million shares were traded on the day, compared to an average of 2.47M shares.


The reasons why investors prefer dividend-paying companies are that dividends generate immediate cash flow and indicate that the company will perform well in the future. Takeda Pharmaceutical Company Limited pays an annual dividend of $1.13, resulting in a dividend yield of 8.34%, and it has a price to earnings (P/E) ratio of 31.05. TAK’s most recent ex-dividend date was 03/30/2022 when it declared a $0.330062 quarterly dividend that was paid in cash on 07/11/2022. Previously, the company paid the dividend on 12/13/2021 with an ex-dividend date of 09/29/2021. The dividend was $0.396898 per share in cash.

Despite rarely being accurate, price targets can exert some form of influence at times, and are often regarded as valuable by markets. According to analysts who have offered 12-month price targets for TAK in the last 3 months, the mean price target is $16.63 with high estimates of $25.81 and low estimates of $12.79. In terms of 52-week highs and lows, TAK has a high of $16.39 and a low of $12.75.

Balance Sheet Annually/Quarterly

As well as showing the assets and liabilities of the company, the balance sheet also shows the amount invested in equity by investors. Investors can analyze a company’s future prospects by calculating its financial ratios based on this information.

Analysts Opinion

After-hours and pre-market trading may carry slightly higher risks than regular market hours. As issuers often announce important financial information outside regular trading hours, extended-hours trading may result in wider spreads for a particular security. That is because extended-hours trading may result in lower liquidity and higher volatility. Currently, 15 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for TAK is Underweight with a score of 3.67. A total of 6 analysts rated the stock as Buy while 2 rated it as Overweight while 6 rated it as Hold. Among the other participants, 1 thought the stock was Underweight and 0 thought it should be Sold.

Related Articles


Please enter your comment!
Please enter your name here

Latest Articles

Receive Best Stock To Trade Before The Opening Bell



100% Free. Stop Anytime. No Spam



The 5 Best Inflation Stocks for 2022




The 5 Best Inflation Stocks for 2022

100% free. stop anytime no spam

Get our free report on the stocks that we recommend for investors who want to protect their portfolios from inflation.